Apply to trial NCT05718791

A few quick questions so the study team can decide if you might be a fit.

RecruitingDiagnostic test

CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening